The gene expression signatures for AP-2alpha are further correlated with sensitivity to cetuximab treatment in HNSCC cell lines and changes in EGFR expression in HNSCC tumors with low CDKN2A gene expression. The gene discussed is CDKN2A; the disease is head and neck squamous cell carcinoma.